– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics ...

On Thursday, an analyst launched coverage of Edgewise Therapeutics (NASDAQ: EWTX) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data ...

When Edgewise Therapeutics last reported its June 2024 balance sheet in August 2024, it had zero debt and cash worth US$512m. Importantly, its cash burn was US$105m over the trailing twelve months.

In September 2024, Edgewise Therapeutics had US$493m in cash, and was debt-free. In the last year, its cash burn was US$110m. So it had a cash runway of about 4.5 years from September 2024.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of ...

Edgewise Therapeutics Inc has a consensus price target of $36.4 based on the ratings of 10 analysts. The high is $51 issued by Piper Sandler on April 2, 2025.

Edgewise Therapeutics has a 1-year low of $11.50 and a 1-year high of $38.12. The stock’s 50-day moving average is $25.20 and its two-hundred day moving average is $28.41.

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule thera ...

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has reported a significant transaction by Chief Scientific Officer Russell Alan J, who sold shares in the company amounting to over $2 million.

– Edgewise leadership to discuss these updates on Thursday, June 26 at 8:30 a.m. Eastern Time at a virtual investor event – BOULDER, Colo., June 26, 2025 /PRNewswire/ -- Edgewise Therapeutics ...

Edgewise Therapeutics has a market capitalisation of US$896m and burnt through US$24m last year, which is 2.7% of the company's market value.